Protocol for Malignant Pleural Mesothelioma Specimen Examination



Protocol for Malignant Pleural Mesothelioma Specimen Examination


































































































































































































































































































































































































































Pleura: Resection


Surgical Pathology Cancer Case Summary (Checklist)


Specimen



____ Pleura



____ Other (specify): ______________________________



____ Not specified


Procedure



____ Pleural decortication



____ Pleurectomy



____ Extrapleural pneumonectomy



____ Other (specify): ______________________________



____ Not specified


Specimen Integrity



____ Intact



____ Disrupted



____ Indeterminate


Specimen Laterality



____ Right



____ Left



____ Not specified


Tumor Site (select all that apply)



____ Parietal pleura



____ Visceral pleura



____ Diaphragm



____ Other (specify): ______________________________



____ Not specified


*Tumor Size (for localized tumors only)



*Greatest dimension: __________ cm



*Additional dimensions: __________ x __________ cm



*____ Cannot be determined


Tumor Focality



____ Localized



____ Diffuse



____ Cannot be determined


Histologic Type



____ Epithelioid mesothelioma



____ Sarcomatoid mesothelioma



____ Biphasic mesothelioma



____ Desmoplastic mesothelioma



____ Other (specify): ______________________________


Tumor Extension (select all that apply)



____ Parietal pleura without involvement of ipsilateral visceral pleura



____ Parietal pleura with focal involvement of ipsilateral visceral pleura



____ Confluent visceral pleural tumor (including fissure)



____ Into but not through diaphragm



____ Lung parenchyma



____ Endothoracic fascia



____ Into mediastinal fat



____ Solitary focus invading soft tissue of chest wall



____ Diffuse or multiple foci invading soft tissue of chest wall



____ Into but not through pericardium



____ Rib(s)



____ Mediastinal organ(s) (specify): ______________________________



____ Other (specify): ______________________________


Margins



____ Not applicable



____ Cannot be assessed



____ Margins negative for mesothelioma



____ Margin(s) involved by mesothelioma





Specify margin(s): ______________________________


Treatment Effect



____ Not applicable



____ Cannot be determined



____ > 50% residual viable tumor



____ < 50% residual viable tumor


Pathologic Staging (pTNM)



TNM descriptors (required only if applicable) (select all that apply)




____ m (multiple primary tumors)




____ r (recurrent)




____ y (post-treatment)



Primary tumor (pT)




____ pTX: Primary tumor cannot be assessed




____ pT0: No evidence of primary tumor




____ pT1a: Tumor limited to ipsilateral parietal pleura ± mediastinal or diaphragmatic pleural involvement; no involvement of visceral pleura




____ pT1b: Tumor involves ipsilateral parietal pleura ± mediastinal or diaphragmatic pleural involvement; tumor also involving visceral pleura




____ pT2: Tumor involves each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura) with at least 1 of the following features:





Involvement of diaphragmatic muscle





Extension of tumor from visceral pleura into underlying pulmonary parenchyma




____ pT3: Locally advanced but potentially resectable tumor that involves all ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura), with at least 1 of the following features:





Involvement of the endothoracic fascia





Extension into mediastinal fat





Solitary completely resectable focus of tumor extending into soft tissues of chest wall





Nontransmural involvement of pericardium




____ pT4: Locally advanced technically unresectable tumor involving all ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic, and visceral pleura), with at least 1 of the following features:





Diffuse extension or multifocal masses of tumor in chest wall ± associated rib destruction





Direct transdiaphragmatic extension to peritoneum





Direct extension to contralateral pleura





Direct extension to mediastinal organs





Direct extension into spine





Extension through internal surface of pericardium ± a pericardial effusion





Tumor involving myocardium



Regional lymph nodes (pN)




____ pNX: Regional lymph nodes cannot be assessed




____ pN0: No regional lymph node metastases




____ pN1: Metastases in ipsilateral bronchopulmonary or hilar lymph nodes




____ pN2: Metastases in subcarinal or ipsilateral mediastinal lymph nodes including ipsilateral internal mammary and peridiaphragmatic nodes




____ pN3: Metastases in contralateral mediastinal, contralateral internal mammary, ipsilateral, or contralateral supraclavicular lymph nodes




____ No nodes submitted or found




Number of lymph nodes examined





Specify: __________





Number cannot be determined (explain): ______________________________




Number of lymph nodes involved





Specify: __________





____ Number cannot be determined (explain): ______________________________



Distant metastasis (pM)



____ Not applicable



____ pM1: Distant metastasis





*Specify site(s), if known: ______________________________



*Additional Pathologic Findings (select all that apply)



*____ None identified



*____ Asbestos bodies



*____ Pleural plaque



*____ Pulmonary interstitial fibrosis



*____ Inflammation (type): ______________________________



*____ Other (specify): ______________________________


*Ancillary Studies (select all that apply)



*____ Immunohistochemical stain(s) result(s) (specify stains): ______________________________



*____ Histochemical stain(s) result(s) (specify stains): ______________________________



*____ Electron microscopy results: ______________________________



*____ Other (specify): ______________________________


*Clinical History (select all that apply)



*____ Neoadjuvant therapy



*____ Other (specify): ______________________________


*Data elements with asterisks are not required. However, these elements may be clinically important but are not yet validated or regularly used in patient management. Adapted with permission from College of American Pathologists, “Protocol for the Examination of Specimens from Patients with Malignant Pleural Mesothelioma.” Web posting date: February, 2011, www.cap.org.

Only gold members can continue reading. Log In or Register to continue

Jul 9, 2016 | Posted by in PATHOLOGY & LABORATORY MEDICINE | Comments Off on Protocol for Malignant Pleural Mesothelioma Specimen Examination
Premium Wordpress Themes by UFO Themes
%d bloggers like this: